Skip to content

Investing
in the Future
of Medicine

We create and invest in biotech companies with innovative technologies that are developing life-saving drugs for patients. We invest in both private and public companies, providing a unique longitudinal view of drug development across the industry.

LEARN MORE

30+ Years of Biotech Investing
59 FDA-approved drugs
40 Companies founded since 2010*

*Companies created by MPM BioImpact include portfolio companies where MPM BioImpact was a co-founder or early lead investor from 2010 to today, representing the period that MPM BioImpact’s strategy has been focused on company creation.

We are Company Creators

We built Orna Therapeutics to create a new class of coding RNA medicines that outperforms mRNA.

Orna’s circular RNA technology (oRNA) and best-in-class non-viral delivery are fundamentally changing the landscape of treatment modalities,* starting with replacing cell therapies and improving vaccines.

“MPM BioImpact’s commitment to creating transformative medicines for patients has been evident since Orna’s inception. MPM BioImpact saw the potential for circular RNA to solve key challenges with existing cell therapies, and it is their vision that drew me to be part of this exciting effort.”**

Tom Barnes
Tom Barnes, Ph.D.
Board Member & SCIENTIFIC ADVISORY BOARD Chair
Amit Munshi
Amit Munshi
CEO
Daniel Anderson
Daniel Anderson, Ph.D.
Co-Founder & Professor, MIT

*Garber, K., "Orna Therapeutics: circular logic," Nature Biotechnology, 05 August 2022, https://doi.org/10.1038/d41587-022-00005-1

**Tom Barnes is not receiving direct compensation for this quote, but has a pecuniary interest that arises from the relationship. Tom receives compensation from certain MPM BioImpact funds.

Meet our Team

MPM BioImpact’s investment team consists of professionals who have dedicated their careers to research and drug development, company creation, corporate strategy, and commercialization. Our Entrepreneur Partners provide deep domain expertise as investor-operators and work with our diverse group of scientists and professionals to develop therapies for diseases with high unmet needs. Collectively, we are a team of deeply experienced company creators who help transform scientific discoveries into breakthrough medicines for the patients that need them most.

Learn about our team of experts

Our Portfolio

Adaptimmune Logo
Aktis Logo
Antiva Biosciences Logo
Arialys Logo
AshiBio Logo
AstronauTx Logo
Crossbow Therapeutics Logo
Cullinan Oncology Logo
Deka Biosciences Logo
digiTx Partners Logo
Dyne Therapeutics Logo
elevatebio Logo
Entrada Therapeutics, Inc. Logo
Firefly Logo
Frontier Medicines Logo
iTeos Logo
NextPoint Therapeutics Logo
ORNA Logo
Photys Therapeutics, Inc. Logo
Protego Logo
Recode TX Logo
Redona Therapeutics Logo
Repare Therapeutics, Inc. (RPTX) Logo
Reunion Neuroscience Logo
SeaWolf Logo
Tetherex Pharmaceuticals Corporation Logo
Tizona Therapeutics, Inc. Logo
Trishula Therapeutics, Inc. Logo
Umoja Biopharma, Inc. Logo
Werewolf Therapeutics, Inc. (HOWL) Logo
Portfolio Companies